Edge's Aneurysm Drug Cuts Hospital Stays, Improves Outcomes
This article was originally published in Scrip
Edge Therapeutics Inc. reported on Feb. 19 during the International Stroke Conference (ISC) in Los Angeles on that EG-1962 cut 3.5 days from time spent in the intensive care unit (ICU) and doubled the likelihood of favorable outcomes for patients with aneurysmal subarachnoid hemorrhage (aSAH).
You may also be interested in...
Company announces plans for layoffs after Phase III NEWTON 2 study of EG-1962 for subarachnoid hemorrhage goes up in smoke.
Poseida, Nkarta and Inventiva raised $224m, $252m and $107.7m, respectively. Also, Forbion raised €185m ($208m) of a new €250m fund and Blackstone closed the last $1.2bn of its $4.6bn fund for public and private company deals, and Ascendis led recent follow-ons with a $569.2m offering.
Some analysts see a 50-50 chance of US FDA approval despite the controversial dataset for the anti-amyloid antibody, but at least one expects an eventual CRL requesting a third Phase III trial.